the Effect of Ginkgo Biloba on Rheumatoid Arthritis Patients

NCT07709312 | Not Yet Recruiting Phase 2

• 1 other identifier: RHDIRB2020110301 REC#460
• Study Type: interventional
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

this study aims to measure The Effect of Gingko Biloba on the Clinical Outcome of Rheumatoid Arthritis Patients ,the outcomes are hsCRp,calprotectin,DAS-28,HAQ-DI

Conditions

Rheumatoid Arthritis (RA); Manegmentof Rheumatoid Arthritis

Outcome Measures

Primary Outcomes (1)

• HsCRP

  * Blood samples will be drawn from the patients at baseline and after 12 weeks of intervention Blood samples will be collected at baseline ,centrifuged and stored as serum at -80 °C until analysis. * Hs-CRP will be evaluated by for each patient at baseline and after 12 weeks using commercial ELISA kits

  baseline and 12 weeks

Secondary Outcomes (3)

• calprotectin

  baseline and 12weeks

• DAS-28

  baseline and 3 months

• Quality of life assessment

  at baseline and after 12 weeks

Study Arms (2)

ginkgo biloba group

EXPERIMENTAL

Ginkgo biloba group: 25 patients will receive Ginkgo biloba treatment (120 mg twice daily for 12 weeks) in addition to their standard treatment.

Drug: Ginkgo Biloba Extract (120 mg ) manufuctured by EMA PHARM

control group

NO INTERVENTION

Control group: 25 patients will receive standard treatment for 12 weeks.

Interventions

Ginkgo Biloba Extract (120 mg ) manufuctured by EMA PHARM DRUG

Ginkgo biloba leaf extract (GBLE) has an antioxidant action as a free radical scavenger, an improving effect on blood flow or microcirculation, and a stimulating effect on neurotransmitters. Besides a direct scavenging action on active oxygen species, GBLE exerts an anti-inflammatory effect on inflammatory cells by suppressing the production of active oxygen and nitrogen species. GBLE inhibited the increase in the products of the oxidative decomposition low-density lipoprotein (LDL), reduced the cell death in various types of neuropathies, and prevented the oxidative damage to mitochondria

ginkgo biloba group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may not qualify if:

• \- 1. Patients with known hypersensitivity to Ginkgo biloba 2. Patients receiving Ginkgo biloba for any other indications 3. Patients on biologic DMARDs 4. Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \< 30 ml/min), 5. Patients with any of the following comorbidities: congestive heart failure, history of myocardial infarction, severe anemia, active infections, other inflammatory diseases, and malignancies.
• \. Patients with other autoimmune diseases

Sponsors & Collaborators

• Ain Shams University: lead

MeSH Terms

Conditions

Arthritis, Rheumatoid

Interventions

Ginkgo biloba extract

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

noran sameh ahmed, bachelor degree in pharmacy

CONTACT

201068397368; nuran.sameh@pharma.asu.edu.eg

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: noran sameh ahmed

Study Record Dates

• First Submitted: July 12, 2026
• First Posted: July 16, 2026
• Study Start: July 15, 2026
• Primary Completion (Estimated): October 15, 2026
• Study Completion (Estimated): October 15, 2026
• Last Updated: July 16, 2026

Record last verified: 2026-07